TITLE

DIAGNOSTIC PRODUCTS/COMPUGEN SIGN IMMUNOASSY PACT

PUB. DATE
March 2003
SOURCE
Worldwide Biotech;Mar2003, Vol. 15 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Compugen Ltd. has granted a license to Diagnostic Products Corporation to develop and commercialize diagnostic assays based on prostate-specific proteins for the screening, detection and monitoring of prostate and other cancers.
ACCESSION #
9213144

 

Related Articles

  • COMPUGEN DEBUTS Z3 AUTOMATED 2D GEL ELECTROPHORESIS SYSTEM.  // Worldwide Biotech;Nov2000, Vol. 12 Issue 11, p1 

    Reports on the launching of the Z3 throughput two-dimensional gel electrophoresis analysis system from Compugen Ltd.

  • TRANSCRIPTION OF ANTISENSE RNA FROM HUMAN GENOME COMMON.  // Biotech Business;May2003, Vol. 16 Issue 5, p7 

    Focuses on the statement issued by Compugen Ltd. regarding the transcription of antisense RNA from the human genome.

  • $500,000 in grants for Compugen.  // Medical Device Daily;6/4/2009, Vol. 13 Issue 106, p8 

    The article announces that the Office of the Chief Scientist of Israel will give Compugen a grant of $500,000.

  • Compugen First Quarter 2011 Webcast and Conference Call Scheduled for Wednesday, May 11 2011 at 10:00 AM EDT.  // Biomedical Market Newsletter;5/5/2011, p200 

    The article reports that Compugen Ltd. will host a live webcast and conference call on May 11, 2011 to review the company's first quarter 2011 results and present an updated slide presentation of the company's current status and outlook.

  • Compugen 2nd Quarter 2012 Conference Call Scheduled for Tues, Aug 7 2012 at 10:00 AM EDT.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article offers information on a conference by Compugen Ltd. to be held at Tel Aviv, Israel on August 7, 2012 in which the 2nd quarter 2012 financial results of the company.

  • Molecular Evolution is Cropping Up. Janssen, Deborah // Genomics & Proteomics;May2002, Vol. 2 Issue 4, p19 

    Investigates the application of computational biology and molecular biology in the development of plant-based products of Compugen in Israel. Isolation of genomic components; Emphasis on gene discovery and gene function identification; Determination of DNA regulatory elements in tomatoes.

  • COMPUGEN DEBUTS GENCARTA PLATFORM FOR GENOME DATABASES ACCESS.  // Worldwide Databases;Nov2000, Vol. 12 Issue 11, p2 

    Reports the launching of Gencarta, a comprehensive platform providing access to genome databases by Compugen Ltd. in the United States. Enhancement of genomic research and discovery for the drug development process; Advantages of using Gencarta intuitive viewers; Company background of Compugen Ltd.

  • Compugen Licenses Its Z4000 System to Organon and Procter & Gamble.  // Drug Discovery & Development;Dec2002, Vol. 5 Issue 11, p22 

    Reports on the decision of Tel-Aviv, Israel-based Compugen Ltd. to license the firm's Z4000 automated system for analyzing two-dimensional gel experiments for proteomic research. Companies that formed licensing agreements with Compugen; Features and capabilities of the system

  • Compugen 1st Qtr 2012 Conference Call Scheduled for May 1 2012.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article presents information on a conference call to be hosted by Compugen Ltd. on May 1, 2012 in which the company will review the financial results for the first quarter of 2012.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics